FrancophonIA/ELRC3.0 huggingface dataset:
English: Tell your doctor right away if you have any of these symptoms or a serious bleeding problem during treatment with Inlyta: black tarry stools, coughing up of blood or bloody sputum, or change in your mental status.
Estonian: Teatage viivitamata oma arstile, kui teil esineb Inlyta-ravi ajal mõni neist sümptomitest või raske veritsusprobleem: must tõrvjas roe, veriköha või veriröga või vaimse seisundi muutus.
English: Ondansetron should not be used during the first trimester of pregnancy.
Estonian: Ondansetrooni ei tohi kasutada esimesel kolmel raseduskuul.
English: Take care to drink sufficient amount of liquid during treatment with mesalazine.
Estonian: Jooge mesalasiinravi ajal piisavalt vett.
English: Tell your doctor if you have any bleeding, coughing up of blood or bloody sputum while on treatment with this medicine.
Estonian: Teatage oma arstile, kui teil esineb veritsust, veriköha või veriröga ajal, kui teid ravitakse selle ravimiga.
English: Lenvatinib
Estonian: Lenvatiniib
English: Frequency: ‘Not known'
Estonian: Esinemissagedus: „Teadmata“
English: What you need to know before you take <product name>
Estonian: 2. Mida on vaja teada enne <ravimi nimetus> võtmist
English: Aflibercept (Zaltrap), bevacizumab, cabozantinib, nintedanib, pazopanib, ponatinib, ramucirumab, regorafenib, sorafenib, tivozanib, vandetanib Summary of product characteristics
Estonian: Aflibertsept (Zaltrap), bevatsisumaab, kabosantiniib, nintedaniib, pasopaniib, ponatiniib, ramutsirumaab, regorafeniib, sorafeniib, tivosaniib, vandetaniib
English: It is not known if <product name> is safe during pregnancy.
Estonian: Ravimi <ravimi nimetus> ohutus rasedatele ei ole teada.
English: You should not use <product name> during the first trimester of pregnancy.
Estonian: Ravimit <ravimi nimetus> ei tohi kasutada esimesel kolmel raseduskuul.
English: Parenteral nutrition products2 containing amino acids and/or lipids with or without admixture of vitamins and/or trace elements - Adverse outcomes in neonates treated with solutions not protected from light (EPITT no 19423)
Estonian: Aminohappeid ja/või lipiide sisaldavad parenteraalse toitmise tooted2 vitamiini- ja/või mikroelemendilisandiga või ilma - negatiivsed tulemused valguse eest kaitsmata lahustega ravitud vastsündinutel (EPITT nr 19423)
English: What you need to know before you take <product name> Warnings and precautions
Estonian: 2. Mida on vaja teada enne <ravimi nimetus omastavas käändes> võtmist Hoiatused ja ettevaatusabinõud
English: Frequency ‘Not known': Aneurysms and artery dissections Footnotes: hIncluding activated partial thromboplastin time prolonged, anal haemorrhage, aneurysm rupture, arterial haemorrhage...
Estonian: Esinemissagedus „teadmata“: aneurüsmid ja arteridissektsioonid Joonealused märkused: hSealhulgas aktiveeritud osalise tromboplastiini aja pikenemine, anaalne verejooks, aneurüsmi rebend, arteriaalne verejooks…
English: Cases of aortic aneurysm and/or dissection (including fatal outcome) have been reported.
Estonian: Teatatud on aordi aneurüsmist ja/või dissektsioonist (sh surmaga lõppenud juhud).
English: the development of the embryo, or foetus, the course of gestation and periand post-natal development.
Estonian: embrüo või loote arengule, raseduse kulule ning sünnitusaegsele jajärgsele arengule.
English: Inlyta may increase the risk of a rupture.
Estonian: Inlyta võib suurendada aneurüsmi rebendi ohtu.
English: The safety of ondansetron for use in human pregnancy has not been established.
Estonian: Ondansetrooni ohutus rasedatel ei ole tõestatud.
English: Talk to your doctor or nurse before taking Inlyta:
Estonian: Enne Inlyta võtmist pidage nõu oma arsti või meditsiiniõega:
English: [For products NOT indicated in neonates BUT in children below 2 years] Light exposure of solutions for intravenous parenteral nutrition, especially after admixture with trace elements and/or vitamins, may lead to generation of peroxides and other degradation products.
Estonian: [Tooted, mis EI OLE näidustatud vastsündinutele, KUID on näidustatud alla 2-aastastele lastele] Intravenoossete parenteraalsete toitelahuste kokkupuude valgusega, eriti pärast mikroelementide ja/või vitamiinide lisamist, võib põhjustada peroksiidide ja muude lagunemisproduktide teket.
English: It is recommended to ensure adequate fluid intake during treatment.
Estonian: Ravi ajal on soovitatav tarbida piisavalt vedelikku.
English: If you are a woman of childbearing potential you may be advised to use effective contraception.
Estonian: Rasestumisvõimelistele naistele võidakse soovitada tõhusate rasestumisvastaste vahendite kasutamist.
English: Special warnings and precautions for use: [For products indicated in neonates (age up to 28 days)] Light exposure of solutions for intravenous parenteral nutrition, especially after admixture with trace elements and/or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products.
Estonian: Erihoiatused ja ettevaatusabinõud kasutamisel [Vastsündinutele (vanus kuni 28 päeva) näidustatud tooted] Intravenoossete parenteraalsete toitelahuste kokkupuude valgusega, eriti pärast mikroelementide ja/või vitamiinide lisamist, võib vastsündinutel mõjutada negatiivselt kliinilist tulemust peroksiidide ja muude lagunemisproduktide tekke tõttu.
English: Frequency ‘Not known': Aneurysms and artery dissections
Estonian: Esinemissagedus „teadmata“: aneurüsmid ja arteridissektsioonid
English: Exposure of <product name> to ambient light, especially after admixtures with trace elements and/or vitamins, generates peroxides and other degradation products that can be reduced by protection from light exposure.
Estonian: Ravimi <ravimi nimetus> kokkupuude väliskeskkonna valgusega, eriti pärast mikroelementide ja/või vitamiinide lisamist, tekitab peroksiide ja muid lagunemisprodukte, mida saab vähendada, kaitstes ravimit valguse eest.
English: Frequency ‘Not known': Aortic aneurysms and dissections* Frequency ‘Not known': Aneurysms and artery dissections*
Estonian: Esinemissagedus „teadmata“: aordi aneurüsmid ja dissektsioonid* Esinemissagedus „teadmata“: aneurüsmid ja arteridissektsioonid*
English: Uncommon severe pain in the back, chest or abdomen associated with tearing in the wall of the aorta and internal bleeding
Estonian: Aeg-ajalt tugev selja-, rinna-või kõhuvalu seoses aordi seina rebenemise ja sisemise verejooksuga Esinemissagedus: „Teadmata“
English: Other side effects include:
Estonian: Muud kõrvaltoimed:
English: Exposure of <product name> to ambient light, especially after admixture with trace elements and/ or vitamins, generates peroxides and other degradation products that can be reduced by protection from light exposure (see sections 4.2, 4.4 and 6.3).
Estonian: Ravimi <ravimi nimetus> kokkupuude väliskeskkonna valgusega, eriti pärast mikroelementide ja/või vitamiinide lisamist, tekitab peroksiide ja muid lagunemisprodukte (vt lõik 4.2, 4.4 ja 6.3).
English: Package leaflet (* include neonates and if product is indicated in such population) [For products used in <neonates and *> children below 2 years] 2.
Estonian: (* lisada vastsündinutele ja , kui ravim on näidustatud kasutamiseks selles patsiendirühmas) [<Vastsündinutel ja *> alla 2-aastastel lastel kasutatavad tooted] 2.
English: Talk to your doctor or nurse before taking <product name>: - If you have been diagnosed with an enlargement or "bulge" of the large blood aortic vessel known as aortic aneurysm.
Estonian: Enne <ravimi nimetus omastavas käändes> võtmist pidage nõu oma arsti või meditsiiniõega: - Kui teil on diagnoositud suur aordilaiend, mida nimetatakse aordi aneurüsmiks.
English: Frequency not known: nephrolithiasis* * See section 4.4 for further information
Estonian: Neerude ja kuseteede häired Esinemissagedus „teadmata“: nefrolitiaas* * Lisateavet vt lõik 4.4
English: - If you have experienced a previous episode of a tear in the aortic wall known as aortic dissection.
Estonian: - Kui teil on varem olnud arteriseina rebend, mida nimetatakse lõhustavaks arterilaiendiks ehk arteri dissektsiooniks.
English: Special warnings and precautions
Estonian: Erihoiatused ja ettevaatusabinõud
English: An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).
Estonian: Veresooneseina laienemine ja nõrgenemine või rebend (aneurüsmid ja arteridissektsioonid).
English: Also, tell your doctor if you have been diagnosed with an aneurysm before taking this medicine.
Estonian: Kui teil on diagnoositud aneurüsm, rääkige enne selle ravimi võtmist oma arstile ka sellest.
English: Kidney stones may develop with use of mesalazine.
Estonian: Mesalasiini kasutamisel võivad tekkida neerukivid.
English: - If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Estonian: - Kui teil on praegu või on varem olnud aneurüsm (veresoone seina laienemine ja nõrgenemine) või arteriseina rebend.
English: If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Estonian: Kui teil on praegu või on varem olnud aneurüsm (veresooneseina laienemine ja nõrgenemine) või veresooneseina rebend.
English: INSTRUCTIONS ON USE (* include neonates and if product is indicated in such population) When used in <neonates and *> children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed.
Estonian: KASUTUSJUHEND (* lisada vastsündinutele ja , kui ravim on näidustatud kasutamiseks selles patsiendirühmas) <Vastsündinutele ja *> alla 2-aastastele lastele manustamisel tuleb (kottides ja manustamiskomplektides olevaid) lahuseid kaitsta valguse eest kuni manustamise lõpuni.
English: When used in children below 2 years, <product name> should be protected from ambient light until administration is completed.
Estonian: Alla 2aastastele lastele manustamisel tuleb kaitsta ravimit <ravimi nimetus> väliskeskkonna valguse eest kuni manustamise lõpuni.
English: An enlargement or "bulge" of the aortic vessel or a tear in the aortic wall (aortic aneurysms and dissections).
Estonian: Aordi laiend või aordiseina rebend (aordianeurüsmid ja dissektsioonid).
English: Before initiating axitinib therapy in patients with pre-existing aneurysms, this risk should be carefully considered.
Estonian: Olemasolevate aneurüsmidega patsientidel tuleb enne ravi alustamist aksitiniibiga seda riski hoolikalt kaaluda.
English: When used in children below 2 years, <product name> should be protected from ambient light until administration is completed (see sections 4.2, 6.3 and 6.6).
Estonian: Alla 2aastastele lastele manustamisel tuleb kaitsta ravimit <ravimi nimetus> väliskeskkonna valguse eest kuni manustamise lõpuni (vt lõik 4.2, 6.3 ja 6.6).
English: When used in neonates and children below 2 years, <product name> should be protected from ambient light until administration is completed.
Estonian: Vastsündinutele ja alla 2-aastastele lastele manustamisel tuleb kaitsta ravimit <ravimi nimetus> väliskeskkonna valguse eest kuni manustamise lõpuni.
English: Before initiating <product name> therapy, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
Estonian: Enne <ravimi nimetus omastavas käändes> ravi kasutamist tuleb riskiteguritega patsientidel (nt hüpertensioon või anamneesis aneurüsm) seda riski hoolikalt hinnata.
English: Axitinib
Estonian: Aksitiniib
English: Before initiating Inlyta, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
Estonian: Enne Inlyta kasutamist tuleb riskiteguritega patsientidel (nt hüpertensioon või anamneesis aneurüsm) seda riski hoolikalt hinnata.
English: Aortic aneurysms and dissections
Estonian: Erihoiatused ja ettevaatusabinõud kasutamisel Aordi aneurüsmid ja dissektsioonid
English: Before initiating <product name>, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
Estonian: Enne <ravimi nimetus omastavas käändes> kasutamist tuleb riskiteguritega patsientidel (nt hüpertensioon või anamneesis aneurüsm) seda riski hoolikalt hinnata.
English: When used in neonates and children below 2 years, <product name> should be protected from ambient light until administration is completed (see sections 4.2, 6.3 and 6.6).
Estonian: Vastsündinutele ja alla 2-aastastele lastele manustamisel tuleb kaitsta ravimit <ravimi nimetus> väliskeskkonna valguse eest kuni manustamise lõpuni (vt lõik 4.2, 6.3 ja 6.6).
English: Tell your doctor if you have an aneurysm (an abnormal balloon-like swelling in the wall of an artery) before taking this medicine.
Estonian: Enne selle ravimi võtmist rääkige oma arstile, kui teil on aneurüsm (ebanormaalne õhupallisarnane väljasopistis arteri seinas).
English: When used in <neonates and *> children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed (see sections 4.4, 6.3 and
Estonian: Manustamisviis<Vastsündinutele ja *> alla 2-aastastele lastele manustamisel tuleb (kottides ja manustamiskomplektides olevaid) lahuseid kaitsta valguse eest kuni manustamise lõpuni (vt lõik 4.4, 6.3 ja 6.6).
English: If you have high blood pressure (only applicable for products containing nintedanib and vandetanib as for the rest of the products, this warning is already included) If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Estonian: Enne <ravimi nimetus omastavas käändes> võtmist pidage nõu oma arsti või meditsiiniõega: Kui teil on kõrge vererõhk (kohaldatakse ainult ravimitele, mis sisaldavad nintedaniibi ja vandetaniibi, sest muudele ravimitele on see hoiatus juba lisatud).
English: When used in <neonates and *> children below 2 years, protect from light exposure, until administration is completed.
Estonian: Erihoiatused ravimpreparaadi hävitamiseks <Vastsündinutele ja *> alla 2-aastastele lastele manustamisel kaitsta valguse eest kuni manustamise lõpuni.
English: When used in <neonates and *> children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed (see section 2).
Estonian: Kuidas ravimit kasutada <Vastsündinutele ja *> alla 2-aastastele lastele manustamisel tuleb (kottides ja manustamiskomplektides olevaid) lahuseid kaitsta valguse eest kuni manustamise lõpuni (vt lõik 2).
English: When used in <neonates and *> children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed.
Estonian: Manustamisviis <Vastsündinutele ja *> alla 2-aastastele lastele manustamisel tuleb (kottides ja manustamiskomplektides olevaid) lahuseid kaitsta valguse eest kuni manustamise lõpuni.
English: When used in <neonates and *> children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed (see sections 4.2, 4.4 and
Estonian: Kõlblikkusaeg <Vastsündinutele ja *> alla 2-aastastele lastele manustamisel tuleb (kottides ja manustamiskomplektides olevaid) lahuseid kaitsta valguse eest kuni manustamise lõpuni (vt lõik 4.2, 4.4 ja 6.6).
English: nitisinone
Estonian: nitisinoon
English: Patients should be monitored at least every six months.
Estonian: Patsiendi seisundit peab kontrollima iga 6 kuu tagant või sagedamini.
English: These amino acids are normally found in proteins in foods and drinks.
Estonian: Need aminohapped on tavaliselt toiduainete ja jookide valkudes.
English: The full EPAR for Nitisinone MDK can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Nitisinone MDK kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nitisinone MendeliKABS on 24 August 2017.
Estonian: Euroopa Komisjon andis Nitisinone MendeliKABS müügiloa, mis kehtib kogu Euroopa Liidus, 24. augustil 2017.
English: The name of the medicine was changed to Nitisinone MDK on 3 October 2017.
Estonian: Ravimi nimetus muudeti Nitisinone MDK 3. oktoober 2017.
English: The capsules are usually swallowed whole, but they may be opened and their contents mixed into a small amount of water or formula just before swallowing.
Estonian: Kapslid neelatakse tavaliselt tervena, kuid kapsli võib avada ja segada selle sisu vahetult enne sissevõtmist väikese koguse veega või toiteseguga.
English: This is a rare disease in which the body is unable to completely break down the amino acid tyrosine and harmful substances are formed, causing serious liver problems and liver cancer.
Estonian: See on haruldane haigus, mille korral organism ei suuda täielikult lagundada aminohapet türosiini, mille tulemusena tekivad kahjulikud ained, mis põhjustavad raskeid maksaprobleeme ja maksavähki.
English: Nitisinone MDK is available as capsules (2 mg, 5 mg and 10 mg).
Estonian: Ravimit Nitisinone MDK turustatakse kapslitena (2 mg, 5 mg ja 10 mg).
English: What measures are being taken to ensure the safe and effective use of Nitisinone MDK?
Estonian: Mis meetmed võetakse, et tagada ravimi Nitisinone MDK ohutu ja efektiivne kasutamine?
English: The recommended starting dose is 1 mg per kilogram body weight per day.
Estonian: Soovitatav algannus on 1 mg kehamassi kilogrammi kohta ööpäevas.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Nitisinone MDK has been shown to have comparable quality and to be bioequivalent to Orfadin.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Nitisinone MDK võrreldav kvaliteet ja bioekvivalentsus ravimiga Orfadin.
English: As for every medicine, the company provided studies on the quality of Nitisinone MDK.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud ravimi Nitisinone MDK kvaliteedi kohta.
English: This means that Nitisinone MDK contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Orfadin.
Estonian: See tähendab, et Nitisinone MDK sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Orfadin, millel juba on Euroopa Liidus müügiluba.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Orfadin, and do not need to be repeated for Nitisinone MDK.
Estonian: Võrdlusravimiga Orfadin on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Nitisinone MDK korrata.
English: Nitisinone MDK is intended for long-term use.
Estonian: Nitisinone MDK on ette nähtud pikaajaliseks kasutamiseks.
English: Because Nitisinone MDK is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Nitisinone MDK on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Tyrosine is broken down in the body by a number of enzymes.
Estonian: Türosiini lagundab organismis mitu ensüümi.
English: The Agency recommended that Nitisinone MDK be approved for use in the EU.
Estonian: Komitee soovitas ravimi Nitisinone MDK kasutamise Euroopa Liidus heaks kiita.
English: What is Nitisinone MDK and what is it used for?
Estonian: Mis on Nitisinone MDK ja milleks seda kasutatakse?
English: Nitisinone MDK is a medicine used to treat hereditary tyrosinaemia type 1 (HT-1).
Estonian: Nitisinone MDK on ravim, mida kasutatakse I tüüpi päriliku türosineemia (HT-1) raviks.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nitisinone MDK have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Nitisinone MDK ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Previously known as Nitisinone MendeliKABS
Estonian: Varem tuntud kui Nitisinone MendeliKABS
English: be started as early as possible and the dose of Nitisinone MDK adjusted according to the patient's response and body weight.
Estonian: Ravi tuleb alustada võimalikult vara ning ravimi Nitisinone MDK annus tuleb kohandada patsiendi ravivastuse ja kehamassi järgi.
English: This is a summary of the European public assessment report (EPAR) for Nitisinone MDK.
Estonian: See on ravimi Nitisinone MDK Euroopa avaliku hindamisaruande kokkuvõte.
English: The diet also needs to be low in phenylalanine, as this is converted into tyrosine in the body.
Estonian: Dieedis peab ka fenüülalaniini sisalduma vähe, sest see muutub organismis türosiiniks.
English: For practical information about using Nitisinone MDK, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Nitisinone MDK kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Patients with HT-1 lack one of these enzymes, so tyrosine is not properly eliminated but is transformed into harmful substances.
Estonian: HT1-ga patsientidel puudub neist üks, mille tõttu jääb türosiin organismi ja see muutub kahjulikeks aineteks.
English: Other information about Nitisinone MDK
Estonian: Muu teave ravimi Nitisinone MDK kohta
English: Why is Nitisinone MDK approved?
Estonian: Miks Nitisinone MDK heaks kiideti?
English: The active substance in Nitisinone MDK, nitisinone, blocks an enzyme that converts tyrosine into harmful substances.
Estonian: Ravimi Nitisinone MDK toimeaine nitisinoon blokeerib türosiini kahjulikeks aineteks muutva ensüümi.
English: For more information about treatment with Nitisinone MDK, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Nitisinone MDK toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Nitisinone MDK is a ‘generic medicine'.
Estonian: Nitisinone MDK on geneeriline ravim.
English: However, as the unconverted tyrosine remains in the body during Nitisinone MDK treatment, patients need to eat a special diet low in tyrosine.
Estonian: Et muundumata türosiin püsib ravimiga Nitisinone MDK toimuva ravi ajal organismis, vajavad patsiendid siiski eridieeti, mis sisaldab türosiini vähe.
English: Nitisinone MDK can only be obtained with a prescription and treatment should be started and monitored by doctors who have experience in the treatment of patients with HT-1.
Estonian: Ravi tohib määrata ja patsienti peab jälgima HT-1-ga patsientide ravis kogenud arst.
English: Nitisinone MDK contains the active substance nitisinone.
Estonian: Nitisinone MDK sisaldab toimeainena nitisinooni.
English: Therefore, the Agency's view was that, as for Orfadin, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Orfadini korral, ületab ravimi Nitisinone MDK kasulikkus sellega kaasnevad riskid.
English: It is not intended to provide practical advice on how to use Nitisinone MDK.
Estonian: Hindamisaruandes ei anta ravimi Nitisinone MDK MLV kasutamise praktilisi nõuandeid.
English: How does Nitisinone MDK work?
Estonian: Kuidas Nitisinone MDK toimib?
English: Nitisinone MDK is used together with a diet that restricts the intake of the amino acids tyrosine and phenylalanine.
Estonian: Ravimit Nitisinone MDK kasutatakse koos aminohappeid türosiini ja fenüülalaniini vähe sisaldava dieediga.
English: How is Nitisinone MDK used?
Estonian: Kuidas ravimit Nitisinone MDK kasutatakse?
English: How has Nitisinone MDK been studied?
Estonian: Kuidas ravimit Nitisinone MDK uuriti?